Despite the anticipated launch of generics of blockbuster brands, an increase in HIV prevalence and continued uptake of premium single-tablet regimens (STRs) will drive continued market growth during 2015-24.
This report addresses the following questions:
- Which brands will drive further growth in the HIV market during 2015-24, and why?
- How successful have Triumeq's and Tivicay's launches been and where are they currently positioned in the treatment algorithm?
- What are physicians' views on the breaking up of fixed-dose combinations to prescribe cheaper separate generic components?
- What percentage of diagnosed patients are currently under medical care and receiving antiretroviral therapy?
- How will recent updates to US and EU treatment guidelines affect prescribing patterns in newly diagnosed patients?
Key Topics Covered:
- Prezista franchise
- Reyataz franchise
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Unmet Needs in HIV
- Impact of Generics
- Sources and Methodology
- Epidemiologist Insight
- Strengths and Limitations
MARKETED DRUGS: HIV
For more information about this report visit http://www.researchandmarkets.com/research/g9snjk/hiv_epidemiology
Related Topics: Immune Disorders Drugs, Infectious Diseases Drugs, HIV/AIDS Drugs
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/hiv-epidemiology-and-patient-based-market-report-2015-2024---continued-uptake-of-premium-single-tablet-regimens-strs-will-drive-continued-market-growth---research-and-markets-300312874.html
SOURCE Research and Markets